Antiangiogenic therapies for mesothelioma
Antiangiogenic therapies for mesothelioma
复制标题
DOI：
10.1016/j.hoc.2005.09.008
复制
发表时间：
2005-12-01
影响因子：
2.4
通讯作者：
Kindler, HL
中科院分区：
文献类型：
--
作者：
Dowell, JE;Kindler, HL
大量的临床前证据表明，血管生成在恶性间皮瘤的发病机制中起着关键作用。在间皮瘤中，血管生成的几种介质似乎是自分泌生长因子，并且在临床前模型中，靶向血管生成的药物产生肿瘤消退。目前有几项临床试验正在评估间皮瘤血管生成抑制剂的疗效。本文详细介绍了这些试验的初步结果和未来的发展方向。
A large body of preclinical evidence suggests that angiogenesis plays a key role in the pathogenesis of malignant mesothelioma. Several mediators of angiogenesis seem to be autocrine growth factors in mesothelioma, and in preclinical models, agents that target angiogenesis produce tumor regression. Several clinical trials are currently evaluating the efficacy of inhibitors of angiogenesis in mesothelioma. This article details the preliminary results of these trials and future directions.